Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The AMSP drug safety program: methods and global results.

R Grohmann1, R R Engel, E Rüther

  • 1Department of Psychiatry, Ludwig-Maximilians University of Munich, Munich, Germany. Renate.Grohmann@med.uni-muenchen.de

Pharmacopsychiatry
|March 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia.

The Psychiatric quarterly·2022
Same author

Assessment of Psychosocial Functioning in a Large Cohort of Patients with Schizophrenia.

The Psychiatric quarterly·2020
Same author

Correlation of CSF- and MRI-Biomarkers and Progression of Cognitive Decline in an Open Label MCI Trial.

The journal of prevention of Alzheimer's disease·2018
Same author

Nutritional Effects on Central Serotonergic Activity: A Hypothesis on the Unconscious Self-manipulation of Mood by Food Intake and Dietary Selection.

Nutritional neuroscience·2016
Same author

[Not Available].

MMW Fortschritte der Medizin·2016
Same author

Genome-wide significant risk factors for Alzheimer's disease: role in progression to dementia due to Alzheimer's disease among subjects with mild cognitive impairment.

Molecular psychiatry·2016

The Arzneimittelsicherheit in der Psychiatry (AMSP) study monitors severe adverse drug reactions in psychiatric patients. This drug safety program uses routine clinical data to assess patient safety and improve psychiatric pharmacovigilance.

Area of Science:

  • Psychiatry
  • Pharmacovigilance
  • Drug Safety

Background:

  • The Arzneimittelsicherheit in der Psychiatry (AMSP) study is an ongoing drug safety program.
  • It evolved from the prior Arzneimittelüberwachung in der Psychiatrie (AMUP) study.
  • Currently, 35 psychiatric hospitals are involved in the AMSP study.

Purpose of the Study:

  • To continuously assess severe adverse drug reactions (ADRs) in psychiatric inpatients.
  • To evaluate ADRs under real-world clinical treatment conditions.
  • To define and analyze severe ADRs within psychiatric care.

Main Methods:

  • Description of the AMSP study methodology.
  • Detailed definitions for classifying ADRs as "severe".
  • Discussion of the implications of these definitions for data evaluation.

Related Experiment Videos

Main Results:

  • Presents overall data on ADR rates from 1993 to 2000.
  • Provides insights into the frequency and nature of severe ADRs in psychiatric inpatients.

Conclusions:

  • The AMSP study provides crucial data on drug safety in psychiatric settings.
  • The defined methodology allows for consistent evaluation of severe ADRs.
  • Findings contribute to improving patient safety in psychiatric pharmacotherapy.